FDA accepts Priority Review of ALXN1210 as treatment for patients with PNH
Alexion announced the FDA has accepted for review the Company’s BLA for approval of ALXN1210, the Company’s investigational long-acting C5 complement inhibitor, for the treatment of patients with paroxysmal nocturnal hemoglobinuria. August 20, 2018